Full report on the toremifene Phase III fracture prevention trial

Toremifene is a selective estrogen receptor modulator or SERM. Some time ago, its developer (GTx, Inc.) initiated a Phase III clinical trial to investigate whether toremifene at a dose of 80 mg/day lowered risk for new vertebral fractures in prostate cancer patients being treated with androgen deprivation therapy (ADT). … READ MORE …

FDA requests more data for toremifene 80 mg

According to a media release from GTx and other reports, the US Food and Drug Administration (FDA) has requested additional information about the effectiveness and safety of toremifene 80 mg before they will be willing to approve a New Drug Application (NDA) for this drug as a treatment to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). … READ MORE …

AUA report and update no. 2: Sunday, April 26, 2009

Two important papers presented this afternoon addressed data on the use of toremifene and denosumab on the bones of men receiving treatment with androgen deprivation therapy (ADT). … READ MORE …

The Tuesday news update: March 3, 2009

Today’s news covers:

  • The ongoing trial of toremifene 20 mg in prevention of prostate cancer
  • Interleukin-6 in the development of prostate cancer
  • Preservation of the fascia and recovery of erectile function post-surgery
  • The use of urethral wall stents and delayed artificial urinary sphincters to treat men with severe, recurrent bladder neck contracture and incontinence after radical prostatectomy … READ MORE …

Thursday’s news reports: February 19, 2009

Today’s important news reports address:

  • 5- and 7-year survival data following iodine-125 permanent implant brachytherapy
  • Risks associated with low levels of lymphocyte apoptosis in patients receiving radiation therapy
  • Stiffening of the large arteries in men receiving antiandrogen therapy
  • The status of the toremifene and denosumab applications for approval for marketing in the USA … READ MORE …